Shu-Ming Kuo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shu-Ming Kuo has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Shin-Ru Shih
Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan, Taiwan
6 shared publications - Bingjie Zhou
University of CAS, Beijing, China
3 shared publications - Cedric A. J. Hutter
Institute of Medical Microbiology, University of Zurich
3 shared publications Ching-Ho Wang
School of Veterinary Medicine, National Taiwan University, Taipei 10617, Taiwan
3 shared publications- Dianfan Li
School of Agriculture and Biotechnology, Sun Yat-sen University
3 shared publications - Dimitri Lavillette
CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS, Shanghai, China
3 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by Wiley in Advanced Science
- Vol. 13 (51) , e76244
Real‐Time and Non‐Invasive Detection of Respiratory Viral Infections Using an Intelligent Odor Monitoring System (IOMS)
Real‐time monitoring of infection‐associated volatile organic compounds (VOCs) offers a non‐invasive pathway for early respiratory infection detection. However, diagnostic precision remains challenged by complex VOC mixtures, low analyte abundance, and significant biological variability. This study introduces an Intelligent Odor Monitoring System (IOMS) guided by infection‐associated biomarker identification. Identification of infection‐associated markers including ethyl lactate and 3,5‐dimethyloctane informed the development of a high‐sensitivity sensor array integrated into an individually ventilated cage (IVC) platform. Operating at 1 Hz, the system generated 3,628,800 longitudinal measurements over a 7‐day infection cycle, capturing distinct odor‐response dynamics between infected and uninfected groups while exploratory principal component analysis supported stage‐associated temporal patterns. Machine‐learning models, including KNN, SVM, and LDA, leveraged these temporal dynamics to model the complete infection cycle with the best internal accuracy reaching 99.88% and model generalizability further supported by an independent blinded cohort. Notably, early sensor‐response shifts were observed at 7–8 hours post‐infection (hpi), and robust model discrimination was achieved by 9 hpi, supporting the feasibility of early‐stage infection monitoring in this murine model. By fusing biomarker‐guided odor sensing with machine learning, the IOMS enables autonomous, continuous surveillance and highlights the potential of longitudinal VOC monitoring for preclinical respiratory infection studies.
- 23 June 2026
- Published by Wiley in Advanced Science
- Vol. 13 (51) , e76244
Open AccessReal‐Time and Non‐Invasive Detection of Respiratory Viral Infections Using an Intelligent Odor Monitoring System (IOMS)
Real‐time monitoring of infection‐associated volatile organic compounds (VOCs) offers a non‐invasive pathway for early respiratory infection detection. However, diagnostic precision remains challenged by complex VOC mixtures, low analyte abundance, and significant biological variability. This study introduces an Intelligent Odor Monitoring System (IOMS) guided by infection‐associated biomarker identification. Identification of infection‐associated markers including ethyl lactate and 3,5‐dimethyloctane informed the development of a high‐sensitivity sensor array integrated into an individually ventilated cage (IVC) platform. Operating at 1 Hz, the system generated 3,628,800 longitudinal measurements over a 7‐day infection cycle, capturing distinct odor‐response dynamics between infected and uninfected groups while exploratory principal component analysis supported stage‐associated temporal patterns. Machine‐learning models, including KNN, SVM, and LDA, leveraged these temporal dynamics to model the complete infection cycle with the best internal accuracy reaching 99.88% and model generalizability further supported by an independent blinded cohort. Notably, early sensor‐response shifts were observed at 7–8 hours post‐infection (hpi), and robust model discrimination was achieved by 9 hpi, supporting the feasibility of early‐stage infection monitoring in this murine model. By fusing biomarker‐guided odor sensing with machine learning, the IOMS enables autonomous, continuous surveillance and highlights the potential of longitudinal VOC monitoring for preclinical respiratory infection studies.
- Open Access
- 27 July 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1
Author Correction: A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection
- 27 July 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1
Open AccessAuthor Correction: A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection
- Open Access
- 30 July 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-13
A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection
SARS-CoV-2, the causative agent of COVID-191, features a receptor-binding domain (RBD) for binding to the host cell ACE2 protein1–6. Neutralizing antibodies that block RBD-ACE2 interaction are candidates for the development of targeted therapeutics7–17. Llama-derived single-domain antibodies (nanobodies, ~15 kDa) offer advantages in bioavailability, amenability, and production and storage owing to their small sizes and high stability. Here, we report the rapid selection of 99 synthetic nanobodies (sybodies) against RBD by in vitro selection using three libraries. The best sybody, MR3 binds to RBD with high affinity (KD = 1.0 nM) and displays high neutralization activity against SARS-CoV-2 pseudoviruses (IC50 = 0.42 μg mL−1). Structural, biochemical, and biological characterization suggests a common neutralizing mechanism, in which the RBD-ACE2 interaction is competitively inhibited by sybodies. Various forms of sybodies with improved potency have been generated by structure-based design, biparatopic construction, and divalent engineering. Two divalent forms of MR3 protect hamsters from clinical signs after live virus challenge and a single dose of the Fc-fusion construct of MR3 reduces viral RNA load by 6 Log10. Our results pave the way for the development of therapeutic nanobodies against COVID-19 and present a strategy for rapid development of targeted medical interventions during an outbreak.
- 30 July 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-13
Open AccessA synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection
SARS-CoV-2, the causative agent of COVID-191, features a receptor-binding domain (RBD) for binding to the host cell ACE2 protein1–6. Neutralizing antibodies that block RBD-ACE2 interaction are candidates for the development of targeted therapeutics7–17. Llama-derived single-domain antibodies (nanobodies, ~15 kDa) offer advantages in bioavailability, amenability, and production and storage owing to their small sizes and high stability. Here, we report the rapid selection of 99 synthetic nanobodies (sybodies) against RBD by in vitro selection using three libraries. The best sybody, MR3 binds to RBD with high affinity (KD = 1.0 nM) and displays high neutralization activity against SARS-CoV-2 pseudoviruses (IC50 = 0.42 μg mL−1). Structural, biochemical, and biological characterization suggests a common neutralizing mechanism, in which the RBD-ACE2 interaction is competitively inhibited by sybodies. Various forms of sybodies with improved potency have been generated by structure-based design, biparatopic construction, and divalent engineering. Two divalent forms of MR3 protect hamsters from clinical signs after live virus challenge and a single dose of the Fc-fusion construct of MR3 reduces viral RNA load by 6 Log10. Our results pave the way for the development of therapeutic nanobodies against COVID-19 and present a strategy for rapid development of targeted medical interventions during an outbreak.
- Open Access
- 23 September 2020
- Published by Springer Nature in Research Square
A potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infection
SARS-CoV-2, the causative agent of COVID-191, recognizes host cells by attaching its receptor-binding domain (RBD) to the host receptor ACE22-7. Neutralizing antibodies that block RBD-ACE2 interaction have been a major focus for therapeutic development8-18. Llama-derived single-domain antibodies (nanobodies, ~15 kDa) offer advantages including ease of production and possibility for direct delivery to the lungs by nebulization19, which are attractive features for bio-drugs against the global respiratory disease. Here, we generated 99 synthetic nanobodies (sybodies) by in vitro selection using three libraries. The best sybody, MR3 bound to RBD with high affinity (KD = 1.0 nM) and showed high neutralization activity against SARS-CoV-2 pseudoviruses (IC50 = 0.40 μg mL-1). Structural, biochemical, and biological characterization of sybodies suggest a common neutralizing mechanism, in which the RBD-ACE2 interaction is competitively inhibited by sybodies. Various forms of sybodies with improved potency were generated by structure-based design, biparatopic construction, and divalent engineering. Among these, a divalent MR3 conjugated with the albumin-binding domain for prolonged half-life displayed highest potency (IC50 = 12 ng mL-1) and protected mice from live SARS-CoV-2 challenge. Our results pave the way to the development of therapeutic nanobodies against COVID-19 and present a strategy for rapid responses for future outbreaks.
- 23 September 2020
- Published by Springer Nature in Research Square
Open AccessA potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infection
SARS-CoV-2, the causative agent of COVID-191, recognizes host cells by attaching its receptor-binding domain (RBD) to the host receptor ACE22-7. Neutralizing antibodies that block RBD-ACE2 interaction have been a major focus for therapeutic development8-18. Llama-derived single-domain antibodies (nanobodies, ~15 kDa) offer advantages including ease of production and possibility for direct delivery to the lungs by nebulization19, which are attractive features for bio-drugs against the global respiratory disease. Here, we generated 99 synthetic nanobodies (sybodies) by in vitro selection using three libraries. The best sybody, MR3 bound to RBD with high affinity (KD = 1.0 nM) and showed high neutralization activity against SARS-CoV-2 pseudoviruses (IC50 = 0.40 μg mL-1). Structural, biochemical, and biological characterization of sybodies suggest a common neutralizing mechanism, in which the RBD-ACE2 interaction is competitively inhibited by sybodies. Various forms of sybodies with improved potency were generated by structure-based design, biparatopic construction, and divalent engineering. Among these, a divalent MR3 conjugated with the albumin-binding domain for prolonged half-life displayed highest potency (IC50 = 12 ng mL-1) and protected mice from live SARS-CoV-2 challenge. Our results pave the way to the development of therapeutic nanobodies against COVID-19 and present a strategy for rapid responses for future outbreaks.
- Open Access
- 1 September 2019
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 17, 10-23
Novel Role for miR-1290 in Host Species Specificity of Influenza A Virus
- 1 September 2019
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 17, 10-23
Open AccessNovel Role for miR-1290 in Host Species Specificity of Influenza A Virus
- Open Access
- 5 July 2017
- Published by American Society for Microbiology in mBio
- Vol. 8 (3) , e00481-17
Inhibition of Avian Influenza A Virus Replication in Human Cells by Host Restriction Factor TUFM Is Correlated with Autophagy
Avian influenza A viruses generally do not replicate efficiently in human cells, but substitution of glutamic acid (Glu, E) for lysine (Lys, K) at residue 627 of avian influenza virus polymerase basic protein 2 (PB2) can serve to overcome host restriction and facilitate human infectivity. Although PB2 residue 627 is regarded as a species-specific signature of influenza A viruses, host restriction factors associated with PB2 627 E have yet to be fully investigated. We conducted immunoprecipitation, followed by differential proteomic analysis, to identify proteins associating with PB2 627 K (human signature) and PB2 627 E (avian signature) of influenza A/WSN/1933(H1N1) virus, and the results indicated that Tu elongation factor, mitochondrial (TUFM), had a higher binding affinity for PB2 627 E than PB2 627 K in transfected human cells. Stronger binding of TUFM to avian-signature PB2 590 G/ 591 Q and PB2 627 E in the 2009 swine-origin pandemic H1N1 and 2013 avian-origin H7N9 influenza A viruses was similarly observed. Viruses carrying avian-signature PB2 627 E demonstrated increased replication in TUFM-deficient cells, but viral replication decreased in cells overexpressing TUFM. Interestingly, the presence of TUFM specifically inhibited the replication of PB2 627 E viruses, but not PB2 627 K viruses. In addition, enhanced levels of interaction between TUFM and PB2 627 E were noted in the mitochondrial fraction of infected cells. Furthermore, TUFM-dependent autophagy was reduced in TUFM-deficient cells infected with PB2 627 E virus; however, autophagy remained consistent in PB2 627 K virus-infected cells. The results suggest that TUFM acts as a host restriction factor that impedes avian-signature influenza A virus replication in human cells in a manner that correlates with autophagy. IMPORTANCE An understanding of the mechanisms that influenza A viruses utilize to shift host tropism and the identification of host restriction factors that can limit infection are both critical to the prevention and control of emerging viruses that cross species barriers to target new hosts. Using a proteomic approach, we revealed a novel role for TUFM as a host restriction factor that exerts an inhibitory effect on avian-signature PB2 627 E influenza virus propagation in human cells. We further found that increased TUFM-dependent autophagy correlates with the inhibitory effect on avian-signature influenza virus replication and may serve as a key intrinsic mechanism to restrict avian influenza virus infection in humans. These findings provide new insight regarding the TUFM mitochondrial protein and may have important implications for the development of novel antiviral strategies.
- 5 July 2017
- Published by American Society for Microbiology in mBio
- Vol. 8 (3) , e00481-17
Open AccessInhibition of Avian Influenza A Virus Replication in Human Cells by Host Restriction Factor TUFM Is Correlated with Autophagy
Avian influenza A viruses generally do not replicate efficiently in human cells, but substitution of glutamic acid (Glu, E) for lysine (Lys, K) at residue 627 of avian influenza virus polymerase basic protein 2 (PB2) can serve to overcome host restriction and facilitate human infectivity. Although PB2 residue 627 is regarded as a species-specific signature of influenza A viruses, host restriction factors associated with PB2 627 E have yet to be fully investigated. We conducted immunoprecipitation, followed by differential proteomic analysis, to identify proteins associating with PB2 627 K (human signature) and PB2 627 E (avian signature) of influenza A/WSN/1933(H1N1) virus, and the results indicated that Tu elongation factor, mitochondrial (TUFM), had a higher binding affinity for PB2 627 E than PB2 627 K in transfected human cells. Stronger binding of TUFM to avian-signature PB2 590 G/ 591 Q and PB2 627 E in the 2009 swine-origin pandemic H1N1 and 2013 avian-origin H7N9 influenza A viruses was similarly observed. Viruses carrying avian-signature PB2 627 E demonstrated increased replication in TUFM-deficient cells, but viral replication decreased in cells overexpressing TUFM. Interestingly, the presence of TUFM specifically inhibited the replication of PB2 627 E viruses, but not PB2 627 K viruses. In addition, enhanced levels of interaction between TUFM and PB2 627 E were noted in the mitochondrial fraction of infected cells. Furthermore, TUFM-dependent autophagy was reduced in TUFM-deficient cells infected with PB2 627 E virus; however, autophagy remained consistent in PB2 627 K virus-infected cells. The results suggest that TUFM acts as a host restriction factor that impedes avian-signature influenza A virus replication in human cells in a manner that correlates with autophagy. IMPORTANCE An understanding of the mechanisms that influenza A viruses utilize to shift host tropism and the identification of host restriction factors that can limit infection are both critical to the prevention and control of emerging viruses that cross species barriers to target new hosts. Using a proteomic approach, we revealed a novel role for TUFM as a host restriction factor that exerts an inhibitory effect on avian-signature PB2 627 E influenza virus propagation in human cells. We further found that increased TUFM-dependent autophagy correlates with the inhibitory effect on avian-signature influenza virus replication and may serve as a key intrinsic mechanism to restrict avian influenza virus infection in humans. These findings provide new insight regarding the TUFM mitochondrial protein and may have important implications for the development of novel antiviral strategies.
- Open Access
- 1 July 2016
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 115 (7) , 510-522
Circulating pattern and genomic characteristics of influenza B viruses in Taiwan from 2003 to 2014
- 1 July 2016
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 115 (7) , 510-522
Open AccessCirculating pattern and genomic characteristics of influenza B viruses in Taiwan from 2003 to 2014
- Open Access
- 12 April 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 24253
Well-tolerated Spirulina extract inhibits influenza virus replication and reduces virus-induced mortality
Influenza is one of the most common human respiratory diseases, and represents a serious public health concern. However, the high mutability of influenza viruses has hampered vaccine development, and resistant strains to existing anti-viral drugs have also emerged. Novel anti-influenza therapies are urgently needed, and in this study, we describe the anti-viral properties of a Spirulina (Arthrospira platensis) cold water extract. Anti-viral effects have previously been reported for extracts and specific substances derived from Spirulina, and here we show that this Spirulina cold water extract has low cellular toxicity, and is well-tolerated in animal models at one dose as high as 5,000 mg/kg, or 3,000 mg/kg/day for 14 successive days. Anti-flu efficacy studies revealed that the Spirulina extract inhibited viral plaque formation in a broad range of influenza viruses, including oseltamivir-resistant strains. Spirulina extract was found to act at an early stage of infection to reduce virus yields in cells and improve survival in influenza-infected mice, with inhibition of influenza hemagglutination identified as one of the mechanisms involved. Together, these results suggest that the cold water extract of Spirulina might serve as a safe and effective therapeutic agent to manage influenza outbreaks, and further clinical investigation may be warranted.
- 12 April 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 24253
Open AccessWell-tolerated Spirulina extract inhibits influenza virus replication and reduces virus-induced mortality
Influenza is one of the most common human respiratory diseases, and represents a serious public health concern. However, the high mutability of influenza viruses has hampered vaccine development, and resistant strains to existing anti-viral drugs have also emerged. Novel anti-influenza therapies are urgently needed, and in this study, we describe the anti-viral properties of a Spirulina (Arthrospira platensis) cold water extract. Anti-viral effects have previously been reported for extracts and specific substances derived from Spirulina, and here we show that this Spirulina cold water extract has low cellular toxicity, and is well-tolerated in animal models at one dose as high as 5,000 mg/kg, or 3,000 mg/kg/day for 14 successive days. Anti-flu efficacy studies revealed that the Spirulina extract inhibited viral plaque formation in a broad range of influenza viruses, including oseltamivir-resistant strains. Spirulina extract was found to act at an early stage of infection to reduce virus yields in cells and improve survival in influenza-infected mice, with inhibition of influenza hemagglutination identified as one of the mechanisms involved. Together, these results suggest that the cold water extract of Spirulina might serve as a safe and effective therapeutic agent to manage influenza outbreaks, and further clinical investigation may be warranted.
- Open Access
- 4 February 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (2) , e0148432
Genomic Signatures for Avian H7N9 Viruses Adapting to Humans
An avian influenza A H7N9 virus emerged in March 2013 and caused a remarkable number of human fatalities. Genome variability in these viruses may provide insights into host adaptability. We scanned over 140 genomes of the H7N9 viruses isolated from humans and identified 104 positions that exhibited seven or more amino acid substitutions. Approximately half of these substitutions were identified in the influenza ribonucleoprotein (RNP) complex. Although PB2 627K of the avian virus promotes replication in humans, 45 of the 147 investigated PB2 sequences retained the E signature at this position, which is an avian characteristic. We discovered 10 PB2 substitutions that covaried with K627E. An RNP activity assay showed that Q591K, D701N, and M535L restored the polymerase activity in human cells when 627K transformed to an avian-like E. Genomic analysis of the human-isolated avian influenza virus is crucial in assessing genome variability, because relationships between position-specific variations can be observed and explored. In this study, we observed alternative positions that can potentially compensate for PB2 627K, a well-known marker for cross-species infection. An RNP assay suggested Q591K, D701N, and M535L as potential markers for an H7N9 virus capable of infecting humans.
- 4 February 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (2) , e0148432
Open AccessGenomic Signatures for Avian H7N9 Viruses Adapting to Humans
An avian influenza A H7N9 virus emerged in March 2013 and caused a remarkable number of human fatalities. Genome variability in these viruses may provide insights into host adaptability. We scanned over 140 genomes of the H7N9 viruses isolated from humans and identified 104 positions that exhibited seven or more amino acid substitutions. Approximately half of these substitutions were identified in the influenza ribonucleoprotein (RNP) complex. Although PB2 627K of the avian virus promotes replication in humans, 45 of the 147 investigated PB2 sequences retained the E signature at this position, which is an avian characteristic. We discovered 10 PB2 substitutions that covaried with K627E. An RNP activity assay showed that Q591K, D701N, and M535L restored the polymerase activity in human cells when 627K transformed to an avian-like E. Genomic analysis of the human-isolated avian influenza virus is crucial in assessing genome variability, because relationships between position-specific variations can be observed and explored. In this study, we observed alternative positions that can potentially compensate for PB2 627K, a well-known marker for cross-species infection. An RNP assay suggested Q591K, D701N, and M535L as potential markers for an H7N9 virus capable of infecting humans.
- 1 November 2014
- Published by Elsevier in Journal of Virological Methods
- Vol. 208, 41-46
Influenza A/B virus detection and influenza A virus subtyping with emphasis on the novel H7N9 virus by using multiplex real-time RT-PCR
- 1 November 2014
- Published by Elsevier in Journal of Virological Methods
- Vol. 208, 41-46
Influenza A/B virus detection and influenza A virus subtyping with emphasis on the novel H7N9 virus by using multiplex real-time RT-PCR